TruSight Oncology 500 ctDNA v2 is a pan-cancer NGS assay that enables in-house comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) in blood plasma for research.
Enable CGP with a pan-cancer panel capable of detecting key IO gene signatures (TMB, MSI) plus all main variant classes from ctDNA in blood plasma.
Assay time
Hands-on time
Input quantity
This product is only available in select locations. Please select the location where you would like this product to be shipped to see availability.
TruSight Oncology 500 ctDNA v2 is a pan-cancer NGS assay that enables in-house comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) in blood plasma for research.
*Not available in all countries. Illumina Connected Insights supports user-defined tertiary analysis through API calls to third-party knowledge sources.
Maximize chances of identifying relevant alterations with the TruSight Oncology 500 product line.
TruSight Oncology 500 ctDNA v2
Analyze circulating tumor DNA (ctDNA) in blood plasma with similar DNA panel content as TruSight Oncology 500.
Assess relevant DNA and RNA cancer biomarkers from FFPE tumor tissue, now including HRD through an accessory kit to assess the Genomic Instability Score (GIS).†
TruSight Oncology 500 High-Throughput Assay
Batch up to 192 samples at a time while using the same panel content and tissue input type as TruSight Oncology 500.
†HRD is only available with the addition of the TruSight Oncology 500 HRD kit to the TruSight Oncology 500 kit. Not available in Japan.
Analytical sensitivity | ≥ 95% (small variants, ≥ 0.5% VAF) |
---|---|
Analytical specificity | ≥ 99.995% (small variants, ≥ 0.5% VAF) |
Assay time | 3-4 days from purified nucleic acid to variant report |
Automation capability | Liquid handling robot(s) |
Automation details | Explore available automation methods |
Cancer type | Pan-cancer, Solid tumor |
Content specifications |
Targeted selection of 523 genes (full coding sequence) for a total of 1.94Mb panel size. • Immuno-oncology biomarker coverage: TMB and MSI • Guideline coverage: Broad coverage of key guidelines for multiple solid tumor types • Clinical trial coverage: Over 600 clinical trials (based on Velsera clinical knowledgebase, as of February 2023) |
Description | Provides a noninvasive research method for comprehensive genomic profiling of liquid biopsy samples (ctDNA from blood plasma). This liquid biopsy approach provides insights about intra- and inter-tumor heterogeneity using a minimally invasive sample collection approach to complement tissue-based CGP. |
Gene count | 523 genes for DNA |
Hands-on time |
~1.5 hr for automated workflow ~2.5 hr for manual workflow |
Input quantity | 20 ng cfDNA (4 ml of plasma) |
Instruments | NovaSeq X System, NovaSeq 6000 System |
Mechanism of action | Hybrid-capture chemistry |
Method | Targeted DNA sequencing, Target enrichment |
Multiplexing |
NovaSeq X Series: 4 samples on 1.5B flow cell, 24 samples on 10B flow cell NovaSeq 6000 System: 8 samples on S2 flow cell, 24 samples on S4 flow cell, 192 indexes maximum |
Nucleic acid type | DNA |
Sample throughput | 4-48 samples/run |
Specialized sample types | Circulating tumor DNA, Blood |
Species category | Human |
Technology | Sequencing |
Variant class | Single nucleotide variants (SNVs), Insertions-deletions (indels), Copy number variants (CNVs) |
To run TruSight Oncology 500 ctDNA v2, you need:
To analyze with the DRAGEN pipeline, you need:
To generate a final variant report, you need:
* Not available in all countries. Illumina Connected Insights supports user-defined tertiary analysis through API calls to third-party knowledge sources.
† Velsera was previously known as Pierian. Other commercial options are available.
TruSight Oncology 500 ctDNA v2 Assay
*NovaSeq 6000Dx (in RUO mode) on-board compatibility coming soon.
†Not available in all countries. Illumina Connected Insights supports user-defined tertiary analysis through API calls to third-party knowledge sources.
Instrument | Recommended number of samples | Read length |
---|---|---|
NovaSeq 6000 System | 24 samples per run (S4 flow cell), 800M paired-end reads, 35,000x coverage |
2 × 150 bp |
NovaSeq 6000 System | 8 samples per run (S2 flow cell), 800M paired-end reads, 35,000x coverage |
2 × 150 bp |
NovaSeq X System | NovaSeq X Series, 4 samples per run (1.5B flow cell), 800M paired-end reads, 35,000x coverage |
2 × 150 bp |
NovaSeq X System | NovaSeq X Series, 24 samples per run (10B flow cell), 800M paired-end reads, 35,000x coverage |
2 × 150 bp |
Next-generation sequencing provides deep insights into the molecular underpinnings of tumors and can help advance the promise of personalized medicine.
Next-generation sequencing enables immuno-oncology researchers to gain insights into immunotherapy response factors and tumor immune evasion mechanisms.
Pathology and clinical cancer research
Our clinical cancer research solutions deliver accurate genomic information, and enable labs to analyze multiple genes in a single test.
TruSight Oncology 500 ctDNA v2 | TruSight Oncology 500 | TruSight Oncology 500 High-Throughput | |||
---|---|---|---|---|---|
Analytical sensitivity | ≥ 95% (small variants, ≥ 0.5% VAF) | ||||
Analytical specificity | ≥ 99.995% (small variants, ≥ 0.5% VAF) | ||||
Assay time | 3-4 days from purified nucleic acid to variant report | 4–5 days from sample to results | 4–5 days from sample to results | ||
Automation capability | Liquid handling robot(s) | Liquid handling robot(s) | Liquid handling robot(s) | ||
Automation details | Explore available automation methods | Explore available automation methods | Explore available automation methods | ||
Cancer type | Pan-cancer, Solid tumor | Pan-cancer, Solid tumor | Pan-cancer, Solid tumor | ||
Content specifications |
Targeted selection of 523 genes (full coding sequence) for a total of 1.94Mb panel size. • Immuno-oncology biomarker coverage: TMB and MSI • Guideline coverage: Broad coverage of key guidelines for multiple solid tumor types • Clinical trial coverage: Over 600 clinical trials (based on Velsera clinical knowledgebase, as of February 2023) |
Targeted sequencing of DNA from 523 genes and RNA from 55 genes for a total of 1.94 Mb panel size. MSI and TMB measurement included. The optional TruSight Oncology 500 HRD kit (not available in Japan) content includes coverage of ~25K SNPs to assess homologous recombination deficiency through a comprehensive genomic instability score (LOH+TAI+LST) powered by Myriad Genetics. | Targeted sequencing of DNA from 523 genes of interest and RNA from 55 genes, for a total of 1.94Mb panel size. MSI and TMB measurement included. | ||
Description | Provides a noninvasive research method for comprehensive genomic profiling of liquid biopsy samples (ctDNA from blood plasma). This liquid biopsy approach provides insights about intra- and inter-tumor heterogeneity using a minimally invasive sample collection approach to complement tissue-based CGP. | Assay that enables comprehensive genomic profiling from FFPE tissue and runs on the NextSeq 550 System or NextSeq 550Dx Instrument (in Research Mode) and can batch up to eight samples at a time. | A high-throughput comprehensive NGS assay to identify key biomarkers in guidelines and >1K clinical trials from a streamlined workflow using the NextSeq 1000, NextSeq 2000, NovaSeq 6000, NovaSeq 6000Dx (in research mode) or the NovaSeq X Series. Includes coverage of immuno-oncology biomarker TMB and MSI. | ||
Gene count | 523 genes for DNA | ||||
Hands-on time |
~1.5 hr for automated workflow ~2.5 hr for manual workflow |
~2.5 hr for automated workflow ~10.5 hr for manual workflow |
~2.5 hr for automated workflow ~10.5 hr for manual workflow |
||
Input quantity | 20 ng cfDNA (4 ml of plasma) | 40 ng DNA and/or 40 ng RNA | 40 ng DNA and/or 40–80 ng RNA | ||
Instruments | NovaSeq X System, NovaSeq 6000 System | NextSeq 550 System, NextSeq 550Dx in Research Mode, NextSeq 500 System | NextSeq 2000 System, NextSeq 1000 System, NovaSeq X System, NovaSeq 6000Dx in Research Mode, NovaSeq 6000 System | ||
Mechanism of action | Hybrid-capture chemistry | ||||
Method | Targeted DNA sequencing, Target enrichment | Targeted DNA sequencing, Targeted RNA sequencing, Target enrichment | Targeted DNA sequencing, Targeted RNA sequencing, Target enrichment | ||
Multiplexing |
NovaSeq X Series: 4 samples on 1.5B flow cell, 24 samples on 10B flow cell NovaSeq 6000 System: 8 samples on S2 flow cell, 24 samples on S4 flow cell, 192 indexes maximum |
Up to 8-plex |
NextSeq 1000 and 2000: P2 flow cell 8 samples, P3 flow cell 24 samples, P4 flow cell 36 samples NovaSeq 6000/Dx: SP flow cell 16 samples, S1 flow cell 32 samples, S2 flow cell 72 samples, S4 flow cell 192 samples NovaSeq X Series*: 1.5B cartridge 32 samples, 10B cartridge 192 samples, 25B 480 samples |
||
Nucleic acid type | DNA | DNA, RNA | DNA, RNA | ||
Sample throughput | 4-48 samples/run | 8 samples/run | NextSeq 1000 and 2000: 8-36 samples/run, NovaSeq 6000/Dx: 16-192 samples/run, NovaSeq X: 32-480 samples/run, NovaSeq X Plus: 32-960 samples/run | ||
Specialized sample types | Circulating tumor DNA, Blood | FFPE tissue | FFPE tissue | ||
Species category | Human | Human | Human | ||
Technology | Sequencing | Sequencing | Sequencing | ||
Variant class | Single nucleotide variants (SNVs), Insertions-deletions (indels), Copy number variants (CNVs) | Gene fusions, Transcript variants, Single nucleotide variants (SNVs), Insertions-deletions (indels), Copy number variants (CNVs), Loss of heterozygosity (LOH), Somatic variants, Novel transcripts, Single nucleotide polymorphisms (SNPs), Structural variants | Gene fusions, Somatic variants, Novel transcripts, Structural variants, Transcript variants, Single nucleotide variants (SNVs), Insertions-deletions (indels), Copy number variants (CNVs) |
* Based on Pierian clinical knowledgebase, as of February 2023.
* NovaSeq 6000Dx System in RUO Mode requires a separate, stand-alone DRAGEN server for secondary analysis.
* NovaSeq 6000Dx (in RUO mode) on-board compatibility coming soon
Synthetic control samples with known variant allele frequency (VAF) for each single nucleotide variant were diluted to values ranging from 0.20%–0.50% VAF and analyzed by TruSight Oncology 500 ctDNA v2.
Synthetic control samples with known VAF for each insertion or deletion were diluted to values ranging from 0.20%–0.50% VAF and analyzed by TruSight Oncology 500 ctDNA v2.
Tumor-only workflow of TSO 500 ctDNA v2 utilizing advanced bioinformatics for germline and CH variant filtering produces highly concordant bTMB compared to a tumor-normal workflow.
Microsatellite instability (MSI) was evaluated in 3 cell lines with known MSI-high status (samples 1–3) and detected down to 0.3% tumor fraction assessing up to ~2300 homopolymer sites.
Lower relative MYC detection due to limit of detection approached faster due to fewer starting copies. Illumina data on file, 2023.
VAF calculated by dividing the total number of supporting reads by the higher depth of the two sides of the breakpoint. Illumina data on file, 2023.
Illumina improved the analysis of circulating tumors with TruSight Oncology ctDNA 500 v2. Learn about new features and benefits in the video.
Interested in learning more about the TruSight Oncology 500 portfolio of products?
Illumina collaborates with National Cancer Center Japan to address a leading cause of death in Asia
Learn about this joint effort to accelerate the development of personalized treatments based on genomic information.
TruSight Oncology 500 ctDNA v2 (24 samples)
20105899
TSO 500 ctDNA v2 Manual Kit
List Price:
Discounts:
TruSight Oncology 500 ctDNA v2 for Use with NovaSeq 6000 S2 Flow Cell (24 samples)
20105901
Mixed Workflow TSO 500 ctDNA v2 + S2 FC Manual Kit
List Price:
Discounts:
TruSight Oncology 500 ctDNA v2 for Use with NovaSeq 6000 S4 Flow Cell (24 samples)
20105902
Mixed Workflow TSO 500 ctDNA v2 + S4 FC Manual Kit
List Price:
Discounts:
TruSight Oncology 500 ctDNA v2 (24 samples) plus Velsera Interpretation Report
20105905
TSO 500 ctDNA v2 Manual Kit + Velsera Interpretation Report
List Price:
Discounts:
TruSight Oncology 500 ctDNA v2 plus Velsera Interpretation Report, for Use with NovaSeq 6000 S2 Flow Cell (24 samples)
20105907
Mixed Workflow TSO 500 ctDNA v2 + S2 FC Manual Kit + Velsera Interpretation Report
List Price:
Discounts:
TruSight Oncology 500 ctDNA v2 plus Velsera Interpretation Report, for Use with NovaSeq 6000 S4 Flow Cell (24 samples)
20105908
Mixed Workflow TSO 500 ctDNA v2 + S4 FC Manual Kit + Velsera Interpretation Report
List Price:
Discounts:
TruSight Oncology 500 ctDNA Kit (48 samples)
20039252
TruSight Oncology 500 ctDNA Kit (Includes DNA library prep and enrichment reagents. Does not include NovaSeq core reagents)
List Price:
Discounts:
TruSight Oncology 500 ctDNA Kit plus Velsera Interpretation Report (16 indexes, 48 Samples)
20043410
Includes library prep and enrichment reagents, plus data interpretation reports (through Velsera Clinical Genomics Workspace software). Does not include NovaSeq System Core Reagents.
List Price:
Discounts:
TruSight Oncology 500 ctDNA Kit, for use with NovaSeq 6000 S2 (48 samples)
20101995
Combination SKU for TSO500 ctDNA and the NovaSeq 6000 S2 Core consumables
List Price:
Discounts:
TruSight Oncology 500 ctDNA Kit, for use with NovaSeq 6000 S4 (48 samples)
20101998
Combination SKU for TSO500 ctDNA and the NovaSeq 6000 S4 Core consumables